{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T18:06:53Z","timestamp":1794852413832,"version":"4.9.1"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T00:00:00Z","timestamp":1713225600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005722","name":"LMU","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005722","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism Reports"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.ymgmr.2024.101085","type":"journal-article","created":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T00:25:35Z","timestamp":1714004735000},"page":"101085","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Acid \u03b1-glucosidase (GAA) activity and glycogen content in muscle biopsy specimens of patients with Pompe disease: A systematic review"],"prefix":"10.1016","volume":"39","author":[{"given":"Benedikt","family":"Schoser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Raben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatbardha","family":"Varfaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Walzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Toscano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgmr.2024.101085_bb0005","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1750-1172-6-34","article-title":"Survival and associated factors in 268 adults with Pompe disease prior to treatment with enzyme replacement therapy","volume":"6","author":"G\u00fcng\u00f6r","year":"2011","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgmr.2024.101085_bb0010","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/brain\/awh384","article-title":"Clinical manifestation and natural course of late-onset Pompe\u2019s disease in 54 Dutch patients","volume":"128","author":"Hagemans","year":"2005","journal-title":"Brain"},{"key":"10.1016\/j.ymgmr.2024.101085_bb0015","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1007\/s00415-015-7664-0","article-title":"Clinical and molecular aspects of 30 patients with late-onset Pompe disease (LOPD): unusual features and response to treatment","volume":"262","author":"Montagnese","year":"2015","journal-title":"J. Neurol."},{"key":"10.1016\/j.ymgmr.2024.101085_bb0020","doi-asserted-by":"crossref","unstructured":"A. Sch\u00fcller, S. Wenninger, N. Strigl-Pill, B. Schoser, Toward deconstructing the phenotype of late-onset Pompe disease, Am. J. Med. Genet. C: Semin. Med. Genet. 160c (2012) 80\u201388. https:\/\/pubmed.ncbi.nlm.nih.gov\/22253010\/.","DOI":"10.1002\/ajmg.c.31322"},{"key":"10.1016\/j.ymgmr.2024.101085_bb0025","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ymgme.2011.06.012","article-title":"Rate of progression and predictive factors for pulmonary outcome in children and adults with Pompe disease","volume":"104","author":"van der Beek","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2024.101085_bb0030","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ymgme.2018.11.011","article-title":"Enzyme enhancement therapeutics for lysosomal storage diseases: current status and perspective","volume":"126","author":"Thomas","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2024.101085_bb0035","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s10545-015-9898-5","article-title":"Response of 33 UK patients with infantile-onset Pompe disease to enzyme replacement therapy","volume":"39","author":"Broomfield","year":"2016","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgmr.2024.101085_bb0040","doi-asserted-by":"crossref","unstructured":"A.T. van der Ploeg, P.R. Clemens, D. Corzo, D.M. Escolar, J. Florence, G.J. Groeneveld, S. Herson, P.S. Kishnani, P. Laforet, S.L. Lake, D.J. Lange, R.T. Leshner, J.E. Mayhew, C. Morgan, K. Nozaki, D.J. Park, A. Pestronk, B. Rosenbloom, A. Skrinar, C.I. van Capelle, N.A. van der Beek, M. Wasserstein, S.A. Zivkovic, A randomized study of alglucosidase alfa in late-onset Pompe\u2019s disease, N. Engl. J. Med. 362 (2010) 1396\u20131406. https:\/\/pubmed.ncbi.nlm.nih.gov\/20393176\/.","DOI":"10.1056\/NEJMoa0909859"},{"key":"10.1016\/j.ymgmr.2024.101085_bb0045","doi-asserted-by":"crossref","unstructured":"E. Kuperus, M.E. Kruijshaar, S.C.A. Wens, J.M. de Vries, M.M. Favejee, J.C. van der Meijden, D. Rizopoulos, E. Brusse, P.A. van Doorn, A.T. van der Ploeg, N. van der Beek, Long-term benefit of enzyme replacement therapy in Pompe disease: a 5-year prospective study, Neurology 89 (2017) 2365\u20132373. https:\/\/pubmed.ncbi.nlm.nih.gov\/29117951\/.","DOI":"10.1212\/WNL.0000000000004711"},{"key":"10.1016\/j.ymgmr.2024.101085_bb0050","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1007\/s13311-018-0655-y","article-title":"Pompe disease: from basic science to therapy","volume":"15","author":"Kohler","year":"2018","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.ymgmr.2024.101085_bb0055","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jpeds.2006.02.035","article-title":"Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease","volume":"149","author":"Kishnani","year":"2006","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgmr.2024.101085_bb0060","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/gim.2012.44","article-title":"The emerging phenotype of long-term survivors with infantile Pompe disease","volume":"14","author":"Prater","year":"2012","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgmr.2024.101085_bb0065","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jpeds.2005.11.033","article-title":"A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease","volume":"148","author":"Kishnani","year":"2006","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgmr.2024.101085_bb0070","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.jval.2012.02.008","article-title":"Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets","volume":"15","author":"van Hout","year":"2012","journal-title":"Value Health"},{"key":"10.1016\/j.ymgmr.2024.101085_bb0075","doi-asserted-by":"crossref","unstructured":"B.J. Ebbink, E. Poelman, I. Plug, M.H. Lequin, P.A. van Doorn, F.K. Aarsen, A.T. van der Ploeg, J.M. van den Hout, Cognitive decline in classic infantile Pompe disease: an underacknowledged challenge, Neurology 86 (2016) 1260\u20131261. https:\/\/pubmed.ncbi.nlm.nih.gov\/26944269\/.","DOI":"10.1212\/WNL.0000000000002523"},{"key":"10.1016\/j.ymgmr.2024.101085_bb0080","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/dmcn.13740","article-title":"Classic infantile Pompe patients approaching adulthood: a cohort study on consequences for the brain","volume":"60","author":"Ebbink","year":"2018","journal-title":"Dev. Med. Child Neurol."},{"key":"10.1016\/j.ymgmr.2024.101085_bb0085","doi-asserted-by":"crossref","unstructured":"J.J.A. van den Dorpel, E. Poelman, L. Harlaar, H.A. van Kooten, L.J. van der Giessen, P.A. van Doorn, A.T. van der Ploeg, J.M.P. van den Hout, N. van der Beek, Distal muscle weakness is a common and early feature in long-term enzyme-treated classic infantile Pompe patients, Orphanet J. Rare Dis. 15 (2020) 247. https:\/\/pubmed.ncbi.nlm.nih.gov\/32928284\/.","DOI":"10.1186\/s13023-020-01482-w"},{"key":"10.1016\/j.ymgmr.2024.101085_bb0090","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ymgme.2010.08.009","article-title":"High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa","volume":"101","author":"de Vries","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2024.101085_bb0095","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ymgme.2017.06.007","article-title":"Effect of enzyme replacement therapy with alglucosidase alfa (Myozyme\u00ae) in 12 patients with advanced late-onset Pompe disease","volume":"122","author":"Papadopoulos","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgmr.2024.101085_bb0100","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1007\/s00415-021-10409-9","article-title":"STIG study: real-world data of long-term outcomes of adults with Pompe disease under enzyme replacement therapy with alglucosidase alfa","volume":"268","author":"Gutschmidt","year":"2021","journal-title":"J. Neurol."},{"key":"10.1016\/j.ymgmr.2024.101085_bb0105","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00415-016-8219-8","article-title":"Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis","volume":"264","author":"Schoser","year":"2017","journal-title":"J. Neurol."},{"key":"10.1016\/j.ymgmr.2024.101085_bb0110","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1038\/mt.2014.138","article-title":"A chaperone enhances blood \u03b1-glucosidase activity in Pompe disease patients treated with enzyme replacement therapy","volume":"22","author":"Parenti","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgmr.2024.101085_bb0115","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1038\/mt.2015.62","article-title":"Pharmacological chaperone therapy: preclinical development, clinical translation, and prospects for the treatment of lysosomal storage disorders","volume":"23","author":"Parenti","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgmr.2024.101085_bb0120","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1089\/hum.2019.109","article-title":"Gene therapy for Pompe disease: the time is now","volume":"30","author":"Colella","year":"2019","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymgmr.2024.101085_bb0125","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1089\/humc.2017.146","article-title":"Safety of Intradiaphragmatic delivery of adeno-associated virus-mediated alpha-glucosidase (rAAV1-CMV-hGAA) gene therapy in children affected by Pompe disease","volume":"28","author":"Corti","year":"2017","journal-title":"Hum. Gene. Ther. Clin. Dev."},{"key":"10.1016\/j.ymgmr.2024.101085_bb0130","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1038\/mt.2008.133","article-title":"Correction of multiple striated muscles in murine Pompe disease through adeno-associated virus-mediated gene therapy","volume":"16","author":"Sun","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgmr.2024.101085_bb0135","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202113968","article-title":"Muscle-directed gene therapy corrects Pompe disease and uncovers species-specific GAA immunogenicity","volume":"14","author":"Eggers","year":"2022","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ymgmr.2024.101085_bb0140","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.ymgmr.2024.101085_bb0145","author":"International Committee of Medical Journal Editors"},{"key":"10.1016\/j.ymgmr.2024.101085_bb0150","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ymthe.2004.09.017","article-title":"Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers","volume":"11","author":"Raben","year":"2005","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgmr.2024.101085_bb0155","first-page":"413","article-title":"A mild form of muscular glycogenosis in two brothers with alpha-1, 4-glucosidase deficiency","volume":"205","author":"Zellweger","year":"1965","journal-title":"Ann. Paediatr."},{"key":"10.1016\/j.ymgmr.2024.101085_bb0160","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/0026-0495(66)90125-9","article-title":"Enzyme patterns in glycogen storage disease type II (Pompe's disease)","volume":"15","author":"Mekanik","year":"1966","journal-title":"Metabolism"},{"key":"10.1016\/j.ymgmr.2024.101085_bb0165","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/brain\/93.3.599","article-title":"Acid maltase deficiency in adults: studies in four cases of a syndrome which may mimic muscular dystrophy or other myopathies","volume":"93","author":"Engel","year":"1970","journal-title":"Brain"},{"key":"10.1016\/j.ymgmr.2024.101085_bb0170","first-page":"39","article-title":"An especially mild myopathic form of glycogenosis type II. Problems of clinical and light microscopic diagnosis","volume":"11","author":"Pongratz","year":"1976","journal-title":"Pathol Eur."},{"key":"10.1016\/j.ymgmr.2024.101085_bb0175","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.1600-0404.1978.tb05868.x","article-title":"Pompe\u2019s disease: ultrastructural alterations of muscle tissue in parents","volume":"57","author":"Pellegrini","year":"1978","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.ymgmr.2024.101085_bb0180","first-page":"406","article-title":"Acid maltase deficiency: clinical and laboratory features of adult-onset cases","volume":"114","author":"Read","year":"2001","journal-title":"N. Z. Med. J."},{"key":"10.1016\/j.ymgmr.2024.101085_bb0185","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/mus.20473","article-title":"Benign course of glycogen storage disease type IIb in two brothers: nature or nurture?","volume":"33","author":"Slonim","year":"2006","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymgmr.2024.101085_bb0190","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1023\/A:1010383421286","article-title":"Enzyme therapy for pompe disease with recombinant human alpha-glucosidase from rabbit milk","volume":"24","author":"Van den Hout","year":"2001","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgmr.2024.101085_bb0195","doi-asserted-by":"crossref","first-page":"e448","DOI":"10.1542\/peds.113.5.e448","article-title":"Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk","volume":"113","author":"Van den Hout","year":"2004","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgmr.2024.101085_bb0200","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.nmd.2004.10.009","article-title":"Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial","volume":"15","author":"Klinge","year":"2005","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymgmr.2024.101085_bb0205","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1055\/s-2005-837543","article-title":"Enzyme replacement therapy in classical infantile pompe disease: results of a ten-month follow-up study","volume":"36","author":"Klinge","year":"2005","journal-title":"Neuropediatrics"},{"key":"10.1016\/j.ymgmr.2024.101085_bb0210","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","article-title":"Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease","volume":"68","author":"Kishnani","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.ymgmr.2024.101085_bb0215","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1016\/j.ymthe.2018.06.023","article-title":"Correction of biochemical abnormalities and improved muscle function in a phase I\/II clinical trial of clenbuterol in Pompe disease","volume":"26","author":"Koeberl","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgmr.2024.101085_bb0220","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/nan.12414","article-title":"Effects of short-to-long term enzyme replacement therapy (ERT) on skeletal muscle tissue in late onset Pompe disease (LOPD)","volume":"44","author":"Ripolone","year":"2018","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.ymgmr.2024.101085_bb0225","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/mus.880140509","article-title":"Infantile Pompe\u2019s disease, lipid storage, and partial carnitine deficiency","volume":"14","author":"Verity","year":"1991","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymgmr.2024.101085_bb0230","first-page":"132","article-title":"Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I\/II clinical trial","volume":"3","author":"Amalfitano","year":"2001","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgmr.2024.101085_bb0235","first-page":"90","article-title":"Morphological changes in late onset acid Maltase deficient patients with splicing gene mutation","volume":"22","author":"Angelini","year":"2003","journal-title":"Acta Myol."},{"key":"10.1016\/j.ymgmr.2024.101085_bb0240","first-page":"71","article-title":"Adult acid maltase deficiency: an open trial with albuterol and branched-chain amino acids","volume":"14","author":"Angelini","year":"2004","journal-title":"Basic Appl Myol."},{"key":"10.1016\/j.ymgmr.2024.101085_bb0245","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/GIM.0b013e31819d0996","article-title":"Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease","volume":"11","author":"Nicolino","year":"2009","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgmr.2024.101085_bb0250","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/0009-8981(78)90191-2","article-title":"Glycogenosis type II: the infantile- and late-onset acid maltase deficiency observed in one family","volume":"87","author":"Koster","year":"1978","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.ymgmr.2024.101085_bb0255","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1212\/WNL.29.3.415","article-title":"Infantile and adult-onset acid maltase deficiency occurring in the same family","volume":"29","author":"Busch","year":"1979","journal-title":"Neurology"},{"key":"10.1016\/j.ymgmr.2024.101085_bb0260","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1399-0004.1981.tb00668.x","article-title":"Identification of heterozygotes for glycogenosis 2 (acid maltase deficiency)","volume":"19","author":"Loonen","year":"1981","journal-title":"Clin. Genet."},{"key":"10.1016\/j.ymgmr.2024.101085_bb0265","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1067\/mpd.2000.107112","article-title":"Identification of two subtypes of infantile acid maltase deficiency","volume":"137","author":"Slonim","year":"2000","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgmr.2024.101085_bb0270","doi-asserted-by":"crossref","first-page":"286","DOI":"10.21037\/atm.2019.06.60","article-title":"Diagnostic tools in late onset Pompe disease (LOPD)","volume":"7","author":"Musumeci","year":"2019","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.ymgmr.2024.101085_bb0275","doi-asserted-by":"crossref","unstructured":"M.Y. Ni\u00f1o, M. Wijgerde, D.O.S. de Faria, M. Hoogeveen-Westerveld, A.J. Bergsma, M. Broeders, N. van der Beek, H.J.M. van den Hout, A.T. van der Ploeg, F.W. Verheijen, W. Pijnappel, Enzymatic diagnosis of Pompe disease: lessons from 28 years of experience, Eur. J. Hum. Genet. 29 (2021) 434\u2013446. https:\/\/pubmed.ncbi.nlm.nih.gov\/33162552\/.","DOI":"10.1038\/s41431-020-00752-2"},{"key":"10.1016\/j.ymgmr.2024.101085_bb0285","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1042\/bj0860011","article-title":"Alpha-glucosidase deficiency in generalized glycogenstorage disease (Pompe\u2019s disease)","volume":"86","author":"Hers","year":"1963","journal-title":"Biochem. J."},{"key":"10.1016\/j.ymgmr.2024.101085_bb0290","first-page":"82","article-title":"Clinical features of Pompe disease","volume":"32","author":"Manganelli","year":"2013","journal-title":"Acta Myol"},{"key":"10.1016\/j.ymgmr.2024.101085_bb0295","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41431-020-00752-2","article-title":"Enzymatic diagnosis of Pompe disease: lessons from 28 years of experience","volume":"29","author":"Nino","year":"2021","journal-title":"Eur. J. Hum. Genet."}],"container-title":["Molecular Genetics and Metabolism Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214426924000387?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214426924000387?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T20:10:20Z","timestamp":1723147820000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214426924000387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":58,"alternative-id":["S2214426924000387"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgmr.2024.101085","relation":{},"ISSN":["2214-4269"],"issn-type":[{"value":"2214-4269","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acid \u03b1-glucosidase (GAA) activity and glycogen content in muscle biopsy specimens of patients with Pompe disease: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgmr.2024.101085","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101085"}}